Rathbones Group PLC Biogen Inc. Transaction History

Rathbones Group PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 09, 2019	SELL	$216.71 - $338.96 $803,560 - $1.26 Million	-3,708 Closed	0 $0
Q4 2018 Feb 12, 2019	BUY	$278.5 - $352.75 $278,500 - $352,750	1,000 Added 36.93%	3,708 $1.12 Million
Q3 2018 Oct 12, 2018	BUY	$293.51 - $383.83 $579,682 - $758,064	1,975 Added 269.44%	2,708 $957,000
Q2 2018 Jul 16, 2018	SELL	$257.52 - $306.91 $33,477 - $39,898	-130 Reduced 15.06%	733 $213,000
Q1 2018 Apr 06, 2018	SELL	$260.13 - $367.91 $15.6 Million - $22.1 Million	-60,150 Reduced 98.59%	863 $236,000
Q4 2017 Jan 24, 2018	BUY	$307.64 - $344.58 $18.5 Million - $20.7 Million	60,100 Added 6582.69%	61,013 $19.4 Million
Q3 2017 Oct 24, 2017	BUY	$281.15 - $329.69 $256,689 - $301,006	913	913 $286,000

1,015

126M

1.12M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $20.3B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Rathbones Group PLC, based on Form 13F filings with the SEC.

Stay updated on Rathbones Group PLC with notifications on news.